PMID: 2513206Jan 1, 1989Paper

Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris

European Journal of Clinical Pharmacology
M PiccaG Pelosi


The antianginal effects of propranolol 160 mg/day, diltiazem 240 mg/day, nicardipine 80 mg/day, nifedipine 40 to 80 mg/day and verapamil 320 mg/day were compared in 12 patients with chronic stable angina pectoris using a symptom-limited exercise test. Compared to placebo propranolol and calcium antagonists similarly reduced (p less than 0.001) the frequency of antianginal attacks and nitroglycerin consumption, and increased exercise tolerance and time to greater than or equal to 1 mm S-T segment depression. After propranolol the pressure-rate product at submaximal and maximal exercise was significantly decreased. The calcium antagonists produced a significant reduction in the submaximal pressure-rate product, but no significant change in the peak pressure-rate product. Maximum ST depression was significantly lower after propranolol and was unchanged after the calcium antagonists. None of the drugs caused significant adverse effects. The results indicate that in patients with stable effort angina pectoris, diltiazem, nicardipine, nifedipine and verapamil were as effective as propranolol in improving exercise tolerance and time to ischaemia, and they did not alter the peak pressure-rate product. Different antianginal mechanisms m...Continue Reading


Mar 4, 1976·The American Journal of Cardiology·S G WarrenE S Orgain
Jan 25, 1985·The American Journal of Cardiology·M B LeonS E Epstein
Oct 6, 1969·JAMA : the Journal of the American Medical Association·E A AmsterdamS Wolfson
Sep 1, 1966·The American Journal of Cardiology·R H GrantK Sinclair
Jul 27, 1968·British Medical Journal·G SandlerS G Thornicroft
Nov 1, 1969·Archives of Internal Medicine·H J ZeftE S Orgain
Nov 17, 1966·The New England Journal of Medicine·S E Epstein, E Braunwald
Oct 1, 1969·Circulation·S Wolfson, R Gorlin
Sep 1, 1966·The American Journal of Cardiology·J Hamer, E Sowton
Mar 29, 1980·Lancet·L H Opie
Jan 1, 1982·International Journal of Cardiology·M R StarlingR A O'Rourke
Dec 23, 1982·The New England Journal of Medicine·E Braunwald
Mar 1, 1983·The American Journal of Cardiology·L G Sherman, C S Liang
May 7, 1983·British Medical Journal·J DeanfieldK Fox
Sep 1, 1981·The American Journal of Cardiology·B SubramanianE B Raftery
Oct 1, 1981·The American Journal of Medicine·H J DargieS Krikler
Feb 18, 1982·The American Journal of Cardiology·K F HossackT A Ports
Jan 1, 1982·Circulation·M B PineR K Wong
Jan 1, 1981·The American Journal of Cardiology·K F Hossack, R A Bruce
Sep 19, 1964·British Medical Journal·S C SRIVASTAVAD J NEWELL
Apr 3, 1965·British Medical Journal·P KEELAN

❮ Previous
Next ❯


Oct 1, 1997·Journal of Clinical Pharmacy and Therapeutics·G KleinM J Kendall
May 26, 1999·Current Problems in Cardiology·M FreherM Gheorgiade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.